Saint Therapeutics Publishes Study on Novel Wound Healing Treatment

　　
Millions of patients worldwide still suffer from poor wound healing and scar formation—areas where significant unmet medical needs remain.

Better healing and reduced scarring could meaningfully improve the quality of life for millions of patients worldwide.

We are proud to share that Saint Therapeutics’ research article,
“Preclinical Efficacy and Safety Study of a Novel Dermal Fibroblast Modulating Drug, SLI-F06, in Cutaneous Wound Healing,”
has been officially published in MedComm.

This study demonstrates the promising preclinical efficacy and safety profile of SLI-F06, a novel fibroblast-modulating therapeutic candidate designed to support tissue repair and improve wound-healing outcomes.

We believe fibroblast modulation may open new possibilities for advancing regenerative medicine approaches in scar reduction and wound healing.

This publication reflects Saint Therapeutics’ continued commitment to translating innovative science into meaningful therapeutic advances for patients worldwide.

We sincerely thank Dr. Eric Kang Ting , Dr. Chia Soo, MD , and all collaborating researchers and partners for their scientific leadership, dedication, and contributions to this important work.

Published article:
Read the publication
http://dx.doi.org/10.1002/mco2.70761

#RegenerativeMedicine #WoundHealing #ScarReduction #Biotech #TranslationalMedicine #Fibroblast #Innovation #SaintTherapeutics